BridgePort Financial Solutions LLC Invests $517,000 in Exelixis, Inc. $EXEL

BridgePort Financial Solutions LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 12,521 shares of the biotechnology company’s stock, valued at approximately $517,000.

Several other institutional investors have also added to or reduced their stakes in EXEL. Richardson Financial Services Inc. boosted its holdings in Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the period. Root Financial Partners LLC purchased a new stake in shares of Exelixis during the third quarter valued at approximately $28,000. Luminist Capital LLC grew its holdings in shares of Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 685 shares during the last quarter. Hantz Financial Services Inc. increased its stake in shares of Exelixis by 940.4% in the second quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after buying an additional 1,025 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in Exelixis during the 2nd quarter valued at $60,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 28,043 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the completion of the transaction, the executive vice president directly owned 374,029 shares in the company, valued at $15,926,154.82. The trade was a 6.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the sale, the director owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This represents a 7.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 172,230 shares of company stock valued at $7,401,923. 2.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on EXEL shares. Stifel Nicolaus set a $43.00 price objective on shares of Exelixis in a research note on Wednesday, November 5th. UBS Group set a $41.00 price objective on Exelixis in a research report on Monday, January 5th. Zacks Research raised Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Truist Financial set a $51.00 price target on shares of Exelixis in a report on Wednesday, January 14th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a report on Tuesday, October 21st. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $46.16.

Exelixis Trading Up 0.1%

NASDAQ EXEL opened at $43.95 on Tuesday. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62. The stock’s fifty day moving average price is $43.70 and its 200-day moving average price is $40.94. The stock has a market cap of $11.78 billion, a P/E ratio of 18.54, a P/E/G ratio of 0.74 and a beta of 0.42.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.